Recurrent or Metastatic Nasopharyngeal Cancer Clinical Trial
Official title:
Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Tislelizumab Combined With Chemotherapy Versus Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
| Verified date | May 2024 |
| Source | BeiGene |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317) Combined With Gemcitabine Plus Cisplatin Versus Placebo Combined With Gemcitabine Plus Cisplatin as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer.
| Status | Active, not recruiting |
| Enrollment | 256 |
| Est. completion date | June 2025 |
| Est. primary completion date | March 26, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility | Key Inclusion Criteria: 1. Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments 2. Aged between 18 to 75 years on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study is taking place) 3. Histologically or cytologically confirmed, recurrent or metastatic NPC 4. Participants must be able to provide fresh or archival tumor tissues (FFPE blocks or approximately 10 [= 6] freshly cut unstained FFPE slides) with an associated pathological report. The archival tumor tissues must be collected within 2 years before screening. In the absence of sufficient archival tumor tissues, a fresh biopsy of a tumor lesion at baseline is mandatory 5. ECOG performance status = 1 6. Must have = 1 measurable lesions as defined per RECIST v1.1 7. Must be treatment-naive for recurrent or metastatic nasopharyngeal cancer (NPC) Key Exclusion Criteria: 1. Participants with locally recurrence suitable for curative surgery or radiotherapy 2. Received any approved systemic anticancer therapy, including hormonal therapy, within 28 days prior to initiation of study treatment. The following exception is allowed: -Palliative radiotherapy for bone metastases or soft tissue lesions should be completed > 7 days prior to baseline imaging. 3. Has received any immunotherapy (including but not limited to interferons, interleukin 2, tumor necrosis factor interleukin, and thymoxin) or any investigational therapies within 14 days or 5 half-lives (whichever is longer) of randomization 4. Received prior therapies targeting PD-1 or PD-L1 5. Active leptomeningeal disease or uncontrolled, untreated brain metastasis 6. Active autoimmune diseases or history of autoimmune diseases that may relapse 7. Any active malignancy = 2 years before randomization except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast) NOTE: Other protocol defined Inclusion/Exclusion criteria may apply. |
| Country | Name | City | State |
|---|---|---|---|
| China | Beijing Cancer Hospital | Beijing | Beijing |
| China | Cancer Hospital Chinese Academy of Medical Science | Beijing | Beijing |
| China | Changsha Central Hospital | Changsha | Hunan |
| China | Hunan Cancer Hospital | Changsha | Hunan |
| China | Sichuan Cancer Hospital | Chengdu | Sichuan |
| China | West China Hospital ,Sichuan University | Chengdu | Sichuan |
| China | Chongqing Three Gorges Central Hospital | Chongqing | Chongqing |
| China | Fujian Provincial Cancer Hospital | Fuzhou | Fujian |
| China | Cancer Center of Guangzhou Medical University | Guangzhou | Guangdong |
| China | Guangdong Provincial People's Hospital | Guangzhou | Guangdong |
| China | Sun Yat-sen Memorial Hospital , Sun Yat-sen University | Guangzhou | Guangdong |
| China | The first Affiliated Hospital of guangzhou University of traditional chinese medicine - Oncology | Guangzhou | Guangdong |
| China | Harbin Medical University Cancer Hospital - Oncology | Haerbin | Heilongjiang |
| China | Chongqing University Cancer Hospital | Haikou | Chongqing |
| China | Hainan General Hospital - Oncology | Haikou | Hainan |
| China | Zhejiang Cancer Hospital | Hangzhou | Zhejiang |
| China | Anhui Provincial Cancer Hospital | Hefei | Anhui |
| China | The First affiliated hospital of Nanchang University | Nanchang | Jiangxi |
| China | Guangxi Medical University Affiliated Tumor Hospital& Oncology Medical College | Nanning | Guangxi |
| China | The People's Hospital of Guangxi Zhuang Autonomous Region | Nanning | Guangxi |
| China | Affiliated hospital of Nantong university | Nantong | Jiangsu |
| China | Affiliated Zhongshan Hospital of Fudan University | Shanghai | Shanghai |
| China | Shanghai East Hospital | Shanghai | Shanghai |
| China | Cancer Hospital of Shantou University Medical College - Oncology | Shantou | Guangdong |
| China | Hubei Cancer Hospital - Oncology | Wuhan | Hubei |
| China | Union Hospital of Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei |
| China | First Affiliated Hospital of Xiamen University | Xiamen | Fujian |
| China | Affiliated Hospital of Guangdong Medical University | Zhanjiang | Guangdong |
| China | People's Hospital of Zhongshan City | Zhongshan | Guangdong |
| China | The Fifth Affiliated Hospital Sun Yat-Sen University | Zhuhai | Guangdong |
| Taiwan | Changhua Christian Hospital | Changhua | NAP |
| Taiwan | Taichung Veterans General Hospital | Taichung | |
| Taiwan | National Cheng Kung University Hospital | Tainan | |
| Taiwan | National Taiwan University Hospital | Taipei | |
| Taiwan | Taipei Veterans General Hospital | Taipei | |
| Thailand | Maharaj Nakorn Chiang Mai Hospital [SSU] | Chiang Mai | Muang |
| Thailand | Vajira Hospital [SSU] | Dusit | Bangkok |
| Thailand | Khon Kaen University, Srinagarind Hospital [SSU] | Khon Kaen | Muang |
| Thailand | Ramathibodi Hospital - Mahidol University - Hematology [SSU] | Ratchathewi | Bangkok |
| Thailand | Prince of Songkla University [SSU] | Song Phi Nong | Hat Yai |
| Lead Sponsor | Collaborator |
|---|---|
| BeiGene |
China, Taiwan, Thailand,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Progression-free Survival | Progression-free survival as assessed by the Independent Review Committee: the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the Independent Review Committee per RECIST v1.1 in an Intent-to-Treat analysis set. | up to 2 years. | |
| Secondary | Overall Survival | The time from the date of randomization to the date of death due to any cause in an Intent-to-Treat analysis set. | up to 2 years. | |
| Secondary | Duration of response | Duration of response as assessed by the Independent Review Committee: the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever comes first, as assessed by the Independent Review Committee per RECIST v1.1 in all randomized participants with documented objective responses. | up to 2 years. | |
| Secondary | Overall response rate | Overall response rate as assessed by the Independent Review Committee: the proportion of participants who had complete response or partial response as assessed by the Independent Review Committee per RECIST v1.1 in all randomized participants with measurable disease at baseline. | up to 2 years. | |
| Secondary | Progression-free survival as assessed by the investigator | The time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1 in an Intent-to-Treat analysis set. | up to 2 years. | |
| Secondary | Progression-free survival after next line of treatment as assessed by the investigator | The time from randomization to second/subsequent disease progression after initiation of new anticancer therapy, or death from any cause, whichever occurs first. | up to 2 years. |